
Gamma-linolenic-acid oils for rheumatoid arthritis: moderate evidence, not a DMARD replacement
Borage, evening-primrose and blackcurrant oils contain GLA and have rheumatoid-arthritis trials, but products and background care differ.
GLA-rich oils may modestly reduce rheumatoid-arthritis symptoms, but they should remain adjuncts to disease-modifying care and require safety review.
GLA comes from several oils
Gamma-linolenic acid, or GLA, is an omega-6 fatty acid found in borage, evening-primrose and blackcurrant seed oils. Products differ greatly in oil amount, GLA concentration and purification. Evidence for a defined GLA dose cannot be transferred to any capsule carrying one of the plant names.
Rheumatoid arthritis is an autoimmune disease, not a nutritional deficiency. Supplements may be studied as adjuncts for symptoms, but disease-modifying antirheumatic drugs are used to control inflammation and prevent damage.
![Oenothera biennis (common evening primrose). Flowers and buds. This plant have been identified with the help of Éric Pensa here : [2] .](/media/assets/cbe5766cb3597eff45f25872b3c3e362b98d7229bb16656ee7957e3b449cb9cf.jpg)
Placebo-controlled trials found symptom signals
A six-month randomized double-blind trial in 56 people with active rheumatoid arthritis tested GLA against placebo and reported improvements in disease activity. An earlier trial using borage-seed oil also found favorable changes in tender and swollen joints.
These studies are small and old, and background treatment has evolved. Their results justify interest but do not prove that current retail products produce the same effect alongside modern treat-to-target regimens.
Longer oil comparisons complicate attribution
An 18-month randomized trial compared borage-seed oil, fish oil and their combination. It asked whether combining GLA with marine omega-3 fatty acids outperformed either oil alone. Multi-oil designs are clinically relevant but make simple ingredient rankings difficult.
Changes in rescue medicine, diet and adherence can influence results over long follow-up. The exact EPA, DHA and GLA exposure matters. A blend cannot credit every favorable outcome to the botanical oil.
The Cochrane review called the evidence moderate
A Cochrane review found moderate evidence that GLA-rich oils may reduce rheumatoid-arthritis pain and disability. It also noted more adverse events numerically and substantial variation among trials. Moderate evidence is not the same as a strong recommendation for every patient.
Review estimates combine oils from different plants because they deliver GLA, but non-GLA constituents and product quality can differ. Consumers still need to match the tested amount and preparation.

Purity and interactions matter
Borage oil should be certified free of harmful pyrrolizidine alkaloids, which can damage the liver. GLA oils may cause digestive symptoms and could affect bleeding, seizures or medicine interactions depending on the product and person.
Rheumatoid-arthritis patients often take immunomodulators, anti-inflammatory medicines and supplements. The complete regimen should be reviewed with the treating team, and new swelling should prompt disease assessment rather than additional oil.
Adjunct evidence has a clear boundary
GLA-rich oils may offer modest symptom benefit for some people, but they have not been shown to replace disease-modifying therapy or reliably prevent structural damage. A symptom improvement should not be interpreted as remission.
Future trials should use modern background care, standardized oils, preregistered outcomes and sufficient safety monitoring. Until then, the evidence supports a supervised adjunct discussion, not self-directed substitution or a broad “omega balance” promise.
Old trials should be tested in modern care
Several favorable GLA studies predate current treat-to-target rheumatoid-arthritis practice and widespread use of biologic and targeted therapies. An adjunct that appeared helpful when background control was weaker may have a smaller added effect today. Conversely, modern stable therapy can make a supplement’s incremental benefit easier to isolate if the trial is designed carefully.
A contemporary study should use verified pyrrolizidine-alkaloid-free oil, state the exact GLA amount and track disease activity, pain, function, rescue medicine and adverse events. It should be large enough to distinguish symptom change from true disease control and should never require participants to abandon effective therapy. Those safeguards would make the evidence relevant to current patients rather than preserving an attractive conclusion from a different treatment era.
Patients and clinicians also need clarity about time to response and what happens after stopping. Fatty-acid incorporation may take time, while rheumatoid-arthritis activity can change rapidly. A study should define rescue rules and protect participants from prolonged uncontrolled disease. It should report radiographic or other structural outcomes only if designed and powered for them. Symptom relief remains valuable, but it cannot be silently upgraded to prevention of joint damage.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.